ECDC and the WHO Regional Office for Europe (WHO/Europe) recently concluded a crucial joint meeting focused on enhancing tuberculosis (TB) surveillance and monitoring across the WHO European Region.
The purpose of this scoping review is to describe and summarise the rationale behind and methodological approaches used to conduct cascade-of-care analyses for TB infection in low-TB incidence countries.
Nearly 7,000 excess deaths from tuberculosis occurred in the WHO European Region in the three years of the pandemic from 2020 - 2022, compared to what experts had expected based on pre-2020 estimates.
During the 2023 West Nile virus transmission season, and as of 4 January 2024, 709 locally acquired human cases of West Nile virus infection, including 67 deaths, were reported by nine European Union countries.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
Campylobacteriosis and salmonellosis were the most frequently reported zoonotic diseases in humans in the EU in 2022. For West Nile virus, an increase of the number of infections was observed.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.